Before you sell to, join or invest in Xilis, Inc.
MentionFox check on Xilis, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/xilis-inc-form-d-25000001
Check Xilis, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Xilis, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Xilis, Inc. filed a Form D with the Securities and Exchange Commission on 2025-04-25.
Xilis, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 25, 2025. The filing reports $19.41M sold. Its industry group is Biotechnology. It names William Smythe (Executive Officer, Director), John de Koning (Director), Alaa Halawa (Director) (SEC Form D, April 25, 2025).
Is this your company?
Sell to companies like Xilis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-04-25 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Xilis, Inc.
Free to see. No signup.
More on the people and the money behind Xilis, Inc., from the filings we hold.
Biotechnology raises by companies based in North Carolina, filed in April 2025, largest first.
Get an email when Xilis, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Xilis, Inc. raises, hires or launches. No email unless you switch it on.
Watch Xilis, Inc. →Get the full cited report on Xilis, Inc.
What the filing shows about Xilis, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Xilis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Xilis, Inc.'s address as 31 Alexandria Way, Durham, NC 27713.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Xilis, Inc. is a registered filer with the SEC (CIK 1796056) and has filed since 2025-04-25. 1 filing is on record, the latest on 2025-04-25.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Xilis, Inc.'s Form D of 2025-04-25 names William Smythe, John de Koning and Alaa Halawa as its officers, directors or promoters.
Its new offerings report $19.41M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Xilis, Inc. has closed. The micro-organosphere (MOS) technology developed at Xilis is now sold by Uniform Bio as MOSgen, a benchtop instrument that makes MOS in your own lab.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
William Smythe is named as Executive Officer and Director on the Form D that Xilis, Inc. filed with the SEC on 25 April 2025, one of 3 people that filing names.
John de Koning is named as Director on the Form D that Xilis, Inc. filed with the SEC on 25 April 2025, one of 3 people that filing names.
Alaa Halawa is named as Director on the Form D that Xilis, Inc. filed with the SEC on 25 April 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-04-25 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Xilis, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Xilis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xilis, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Xilis, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Xilis, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-04 (xilis.com).
Each opens in a new tab, filled in for Xilis, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/xilis-inc-form-d-25000001